Advances in interleukin 2 receptor targeted treatment

Morris, John C; Waldmann, Thomas A

doi:10.1136/ard.59.suppl_1.i109

Cited by 131T-cell and B-cell ImmunologyCytokine Signaling Pathways and InteractionsMonoclonal and Polyclonal Antibodies Research

Advances in interleukin 2 receptor targeted treatment

Open access

Morris, John C, Waldmann, Thomas A·2000·Annals of the Rheumatic Diseases

DOI 10.1136/ard.59.suppl_1.i109

Open this paper in CoChat — free account Open PDF

Abstract

T cell activation and cellular immune responses are modulated by interleukin 2 (IL2) through binding to its corresponding cell surface receptor. Three forms of the receptor are recognised based on IL2 binding affinity. The high affinity receptor is a heterotrimer composed of alpha, beta, and gamma(c)-polypeptide chains. The 55 kDa alpha-chain also known as the Tac (T cell activation) antigen or CD-25 is a unique subunit of the high affinity IL2 receptor (IL2Ralpha). Resting T cells express few IL2Ralpha, however, when activated, the expression of ILR2alpha rapidly increases. The IL2Ralpha is shed from the cell surface and is measurable in the serum as a 45 kDa soluble form (s-Tac or s-IL2Ralpha). Serum concentrations of s-Tac can be used as a surrogate marker for T cell activation and IL2Ralpha expression. IL2Ralpha is over expressed by T cells in a number of autoimmune diseases, allograft rejection and a variety of lymphoid neoplasms. IL2 induced proliferation of T cells can be inhibited by the murine monoclonal antibody (anti-Tac) directed against the alpha-chain of the IL2R. Through molecular engineering, murine anti-Tac has been humanised reducing its immunogenicity without changing its specificity. Humanised anti-Tac (HAT) has been shown to reduce the incidence of renal and cardiac allograft rejection as well as decrease the severity of graft versus host disease in patients undergoing HLA matched allogeneic bone marrow transplantation. IL2Ralpha targeted treatment with radioimmunoconjugates of anti-Tac and immunotoxins has shown promise in the treatment of CD25 expressing lymphomas.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1136/ard.59.suppl_1.i109

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In some studies, habitual short sleep duration has been found to be unrelated to WBC counts, NK-cell activity, and telomere length.
“in some of those studies, habitual short sleep duration has been found to be unrelated to WBC counts (156, 405), NK-cell activity (391), and telomere length (451)”
From The Sleep-Immune Crosstalk in Health and Disease (2019) · cites this paper as [391]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows
Morgan, D. A., Ruscetti, F. W., & Gallo, R. C. (1976) · Science · doi:10.1126/science.181845 · Cited by 2,509 · see citing works
Adult T-cell leukemia: clinical and hematologic features of 16 cases
Uchiyama, T., Yodoi, J., Sagawa, K., Takatsuki, K., & Uchino, H. (1977) · Blood · doi:10.1182/blood.v50.3.481.bloodjournal503481 · Cited by 2,315 · see citing works
Interleukin-2: Inception, Impact, and Implications
Smith, K. A. (1988) · Science · doi:10.1126/science.3131876 · Cited by 2,166 · see citing works
Long term culture of tumour-specific cytotoxic T cells
Gillis, S. A., & Smith, K. A. (1977) · Nature · doi:10.1038/268154a0 · Cited by 1,396 · see citing works
Graft-versus-Host Disease
Ferrara, J. L. M., & Deeg, H. J. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103073241005 · Cited by 1,241 · see citing works
Structure and expression of a cloned cDNA for human interleukin-2
Taniguchi, T., Matsui, H., Fujita, T., Takaoka, C., Kashima, N., Yoshimoto, R., & Hamuro, J. (1983) · Nature · doi:10.1038/302305a0 · Cited by 1,182 · see citing works
T cell growth factor receptors. Quantitation, specificity, and biological relevance
Robb, R., Munck, A. U., & Smith, K. (1981) · The Journal of Experimental Medicine · doi:10.1084/jem.154.5.1455 · Cited by 1,062 · see citing works
Interleukin-2–Receptor Blockade with Daclizumab to Prevent Acute Rejection in Renal Transplantation
Vincenti, F., Kirkman, R. L., Light, S. E., Bumgardner, G. L., Pescovitz, M. D., Halloran, P. F., Neylan, J. F., Wilkinson, A. H., Ekberg, H., Gaston, R. S., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801153380304 · Cited by 861 · see citing works
Molecular cloning and expression of cDNAs for the human interleukin-2 receptor
Leonard, W. J., Depper, J. M., Crabtree, G. R., Rudikoff, S., Pumphrey, J. G., Robb, R. J., Krönke, M., Svetlik, P. B., Peffer, N. J., Waldmann, T. A., et al. (1984) · Nature · doi:10.1038/311626a0 · Cited by 850 · see citing works
Self-citation
Cloning of the γ Chain of the Human IL-2 Receptor
Takeshita, T., Asao, H., Ohtani, K., Ishii, N., Kumaki, S., Tanaka, N., Munakata, H., Nakamura, M., & Sugamura, K. (1992) · Science · doi:10.1126/science.1631559 · Cited by 840 · see citing works
One molecule of diphtheria toxin fragment a introduced into a cell can kill the cell
Yamaizumi, M., Mekada, E., Uchida, T., & Okada, Y. (1978) · Cell · doi:10.1016/0092-8674(78)90099-5 · Cited by 745 · see citing works
A humanized antibody that binds to the interleukin 2 receptor.
Queen, C., Schneider, W. P., Selick, H. E., Payne, P. W., Landolfi, N. F., Duncan, J. F., Avdalovic, N. M., Levitt, M., Junghans, R. P., & Waldmann, T. A. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.24.10029 · Cited by 627 · see citing works
Self-citation
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells
Witthuhn, B. A., Silvennoinen, O., Miura, O., Lai, K. S., Cwik, C., Liu, E. T., & Ihle, J. N. (1994) · Nature · doi:10.1038/370153a0 · Cited by 613 · see citing works
The Soluble Interleukin-2 Receptor: Biology, Function, and Clinical Application
Rubin, L. A., & Nelson, D. L. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-8-619 · Cited by 602 · see citing works
Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2
Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y.-Q., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., & O’Shea, J. J. (1994) · Nature · doi:10.1038/370151a0 · Cited by 593 · see citing works
Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity Conditions
Sharon, M., Klausner, R. D., Cullen, B. R., et al. (1986) · Science · doi:10.1126/science.3095922 · Cited by 580 · see citing works
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J. M., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524 · see citing works
Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex.
Tsudo, M., Kozak, R. W., Goldman, C. K., et al. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9694 · Cited by 469 · see citing works
The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes
Waldmann, T. A. (1986) · Science · doi:10.1126/science.3008337 · Cited by 453 · see citing works
Self-citation
Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies
Kreitman, R. J., Wilson, W. H., White, J. D., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1622 · Cited by 420 · see citing works
HUMAN T CELL LEUKEMIA VIRUS TYPE I (HTLV-I) AND HUMAN DISEASES
Uchiyama, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.15 · Cited by 390 · see citing works
Treatment of Adult T-Cell Leukemia–Lymphoma with a Combination of Interferon Alfa and Zidovudine
Gill, P. S., Harrington, W. J., Kaplan, M. H., Ribeiro, R. C., Bennett, J. M., Liebman, H. A., Bernstein-Singer, M., Espina, B. M., Cabral, L., Allen, S. L., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506293322603 · Cited by 369 · see citing works
DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTS
Prentice, H. G., Janossy, G., Price-Jones, L., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92848-4 · Cited by 360 · see citing works
A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. II. Expression of Tac antigen on activated cytotoxic killer T cells, suppressor cells, and on one of two types of helper T cells.
Uchiyama, T., Nelson, D. L., Fleisher, T. A., & Waldmann, T. A. (1981) · The Journal of Immunology · doi:10.4049/jimmunol.126.4.1398 · Cited by 345 · see citing works
Self-citation
The interleukin-2 receptor.
Waldmann, T. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)49895-x · Cited by 340 · see citing works
Self-citation
REDUCTION OF ACUTE RENAL ALLOGRAFT REJECTION BY DACLIZUMAB1
Nashan, B., Light, S. E., Hardie, I. R., et al. (1999) · Transplantation · doi:10.1097/00007890-199901150-00019 · Cited by 309 · see citing works
RISK FACTORS FOR ACUTE GRAFT-VERSUS-HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION
Weisdorf, D. J., Haake, R. J., Blazar, B. R., Miller, W. J., McGlave, P. B., Ramsay, N. K. C., Kersey, J., & Filipovich, A. H. (1991) · Transplantation · doi:10.1097/00007890-199106000-00010 · Cited by 275 · see citing works
Prevention of Rejection in Cardiac Transplantation by Blockade of the Interleukin-2 Receptor with a Monoclonal Antibody
Beniaminovitz, A., Itescu, S., Lietz, K., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003023420902 · Cited by 265 · see citing works
Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial
Nussenblatt, R. B., Fortin, É., Schiffman, R. M., Rizzo, L. V., Smith, J. A., Veldhuisen, P. C. V., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.13.7462 · Cited by 259 · see citing works
Self-citation
Characterization and distribution of nucleic acid sequences of a novel type C retrovirus isolated from neoplastic human T lymphocytes.
Reitz, M. S., Poiesz, B. J., Ruscetti, F. W., & Gallo, R. C. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.3.1887 · Cited by 257 · see citing works
Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with Yttrium-90-labeled anti-Tac [see comments]
Waldmann, T. A., White, J., Carrasquillo, J. A., Reynolds, J., Paik, C. H., Gansow, O. A., Brechbiel, M., Jaffe, E., Fleisher, T., & Goldman, C. K. (1995) · Blood · doi:10.1182/blood.v86.11.4063.bloodjournal86114063 · Cited by 246 · see citing works
Self-citation
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Przepiorka, D., Kernan, N. A., Ippoliti, C. M., et al. (2000) · Blood · doi:10.1182/blood.v95.1.83 · Cited by 241 · see citing works
Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease
Przepiorka, D., Kernan, N. A., Ippoliti, C. M., et al. (2000) · Blood · doi:10.1182/blood.v95.1.83.001k18_83_89 · Cited by 239 · see citing works
A Monoclonal Antibody 7G7/B6, Binds to an Epitope on the Human Interleukin-2 (IL-2) Receptor That is Distinct From That Recognized by IL-2 or Anti-Tac
Rubin, L. A., Kurman, C. C., Biddison, W. E., Goldman, N. D., & Nelson, D. L. (1985) · Hybridoma · doi:10.1089/hyb.1985.4.91 · Cited by 233 · see citing works
Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/lymphoma virus negative Sézary leukemia, and their distinction using anti-Tac. Monoclonal antibody identifying the human receptor for T cell growth factor.
Waldmann, T. A., Greene, W. C., Sarin, P. S., Saxinger, C. W., Blayney, D. W., Blattner, W. A., Goldman, C. K., Bongiovanni, K. F., Sharrow, S. O., & Depper, J. M. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111379 · Cited by 225 · see citing works
Self-citation
Characterization of the interleukin 2 receptor beta chain using three distinct monoclonal antibodies.
Tsudo, M., Kitamura, F., & Miyasaka, M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.6.1982 · Cited by 213 · see citing works
The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
Ta, W., White, J., Goldman, C. K., Top, L. E., Grant, A., Bamford, R. N., Roessler, E., Horak, I. D., Zaknoen, S. L., & Kasten-Sportès, C. (1993) · Blood · doi:10.1182/blood.v82.6.1701.1701 · Cited by 207 · see citing works
Structure/function analysis of interleukin-2-toxin (DAB486-IL-2). Fragment B sequences required for the delivery of fragment A to the cytosol of target cells.
Williams, D. P., Snider, C. E., Strom, T. B., et al. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38482-0 · Cited by 186 · see citing works
The Immunopathophysiology of Acute Graft‐Versus‐Host‐Disease
Ferrara, J. L. M., Cooke, K. R., Pan, L., & Krenger, W. (1996) · Stem Cells · doi:10.1002/stem.140473 · Cited by 182 · see citing works
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor
Anasetti, C., Hansen, J., Ta, W., et al. (1994) · Blood · doi:10.1182/blood.v84.4.1320.1320 · Cited by 170 · see citing works
Structure-function relationships for the IL 2-receptor system. IV. Analysis of the sequence and ligand-binding properties of soluble Tac protein.
Robb, R. J., & Kutny, R. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.3.855 · Cited by 167 · see citing works
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders.
Junghans, R. P., Waldmann, T. A., Landolfi, N. F., Avdalovic, N. M., Schneider, W. P., & Queen, C. (1990) · PubMed · Cited by 150 · see citing works
Self-citation
A PHASE I TRIAL OF HUMANIZED ANTI-INTERLEUKIN 2 RECEPTOR ANTIBODY IN RENAL TRANSPLANTATION1
Vincenti, F. G., Lantz, M. V., Birnbaum, J. L., et al. (1997) · Transplantation · doi:10.1097/00007890-199701150-00007 · Cited by 147 · see citing works
Antitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides
Saleh, M. N., LeMaistre, C. F., Kuzel, T. M., et al. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70403-7 · Cited by 138 · see citing works
The use of antibodies against the IL-2 receptor in transplantation
Waldmann, T. A., & O’Shea, J. J. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80215-x · Cited by 135 · see citing works
Self-citation
Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia.
Shimoyama, M., Ota, K., Kikuchi, M., et al. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.7.1088 · Cited by 134 · see citing works
In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration.
Lotze, M. T., Custer, M. C., Sharrow, S. O., Rubin, L. A., Nelson, D. L., & Rosenberg, S. A. (1987) · PubMed · Cited by 132 · see citing works
Serum levels of interleukin‐2 receptor and activity of rheumatic diseases characterized by immune system activation
Campen, D. H., Horwitz, D. A., Quismorio, F. P., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311103 · Cited by 129 · see citing works
Elevated soluble interleukin‐2 receptor levels in the sera and synovial fluids of patients with rheumatoid arthritis
Keystone, E. C., Snow, K. M., Bombardier, C., et al. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780310704 · Cited by 114 · see citing works
Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.
Brown, P. S., Parenteau, G. L., Dirbas, F. M., et al. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2663 · Cited by 103 · see citing works
Effect of Human T-Lymphotropic Virus Type I Infection on Non-Hodgkin's Lymphoma Incidence
Cleghorn, F. R., Manns, A., Falk, R. T., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.1009 · Cited by 96 · see citing works
Serum interleukin-2-receptor in rheumatoid arthritis: A prognostic indicator of disease activity?
Wood, N. C., Symons, J. A., & Duff, G. W. (1988) · Journal of Autoimmunity · doi:10.1016/0896-8411(88)90005-4 · Cited by 86 · see citing works
EXPERIENCE WITH DACLIZUMAB IN LIVER TRANSPLANTATION
Hirose, R., Roberts, J. P., Quan, D. J., et al. (2000) · Transplantation · doi:10.1097/00007890-200001270-00019 · Cited by 78 · see citing works
Serum concentration of the soluble interleukin-2 receptor for monitoring acute graft-versus-host disease.
Miyamoto, T., Akashi, K., Hayashi, S., et al. (1996) · PubMed · Cited by 77 · see citing works
Daclizumab
Wiseman, L. R., & Faulds, D. M. (1999) · Drugs · doi:10.2165/00003495-199958060-00006 · Cited by 71 · see citing works
Cytokine levels in serum and synovial fluid of patients with juvenile rheumatoid arthritis.
Madson, K. L., Moore, T. L., Lawrence, J. M., et al. (1994) · PubMed · Cited by 71 · see citing works
A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation
Berard, J. L., Velez, R. L., Freeman, R. B., et al. (1999) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.19.15.1127.30582 · Cited by 69 · see citing works
Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.
Junghans, R. P., & Waldmann, T. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.4.1587 · Cited by 66 · see citing works
Self-citation
Monitoring soluble interleukin-2 receptor levels in related and unrelated donor allogeneic bone marrow transplantation
Foley, R., Couban, S., Walker, I., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701163 · Cited by 62 · see citing works
Soluble interleukin-2 receptor serum levels after allogeneic bone marrow transplantation as a marker for GVHD
Grimm, J., Zeller, W., & Zander, A. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701041 · Cited by 62 · see citing works
Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin 2 (IL-2) receptor
Harris, D., Sakiestewa, D., Lyons, C., et al. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701535 · Cited by 62 · see citing works
The cytokine modulation of acute graft-versus-host disease.
Ferrara, J. L. M. (1998) · PubMed · Cited by 49 · see citing works
Humanized Mik beta 1, a humanized antibody to the IL-2 receptor beta -chain that acts synergistically with humanized anti-TAC.
Hakimi, J., Ha, V. C., Lin, P. R., et al. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.2.1075 · Cited by 48 · see citing works
HTLV‐I and HTLV‐II world‐wide distribution: Reanalysis of 4,832 immunoblot results
Madeleine, M. M., Wiktor, S. Z., Goedert, J. J., et al. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540216 · Cited by 45 · see citing works
The soluble interleukin‐2 receptor in rheumatic disease
Rubin, L. A. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330814 · Cited by 42 · see citing works
Graft-Versus-Host Disease
Parkman, R. (1991) · Annual Review of Medicine · doi:10.1146/annurev.me.42.020191.001201 · Cited by 38 · see citing works
Soluble interleukin 2 receptors in patients after bone marrow transplantation.
Siegert, W., Josimovic‐Alasevic, O., Schwerdtfeger, R., et al. (1990) · PubMed · Cited by 37 · see citing works
Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course
Swaak, A. J. G., Hintzen, R. Q., Huysen, V., et al. (1995) · Clinical Rheumatology · doi:10.1007/bf02208342 · Cited by 33 · see citing works
Soluble interleukin 2 receptor levels in serum and its relationship to T cell abnormality and clinical manifestations of the disease in patients with systemic lupus erythematosus.
Raziuddin, S., Al‐Janadi, M., & Al-Wabel, A. (1991) · PubMed · Cited by 31 · see citing works
Clinical Relevance of Serum Soluble Interleukin-2 Receptor Levels in Acute and Chronic Graft-versus-Host Disease
Kobayashi, S., Imamura, M., Hashino, S., et al. (1997) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199709058342 · Cited by 28 · see citing works
Biophysical Characterization of a Recombinant Soluble Interleukin 2 Receptor (Tac)
Junghans, R. P., Stone, A. L., & Lewis, M. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.18.10453 · Cited by 21 · see citing works
Immunopathology of Experimental Autoimmune Uveoretinitis in Primates
Fujino, Y., Li, Q., Chung, H., et al. (1992) · Autoimmunity · doi:10.3109/08916939209112339 · Cited by 21 · see citing works
Pleural fluid soluble interleukin 2 receptor in rheumatoid arthritis and systemic lupus erythematosus.
Pettersson, T., Söderblom, T., Nyberg, P., et al. (1994) · PubMed · Cited by 18 · see citing works
Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.
Chan, E. Y. Y., Lau, C. S., & Zola, H. (1996) · Journal of Clinical Pathology · doi:10.1136/jcp.49.8.660 · Cited by 17 · see citing works
Effects of in-vivo administration of a monoclonal antibody specific for the interleukin-2 receptor on the acute graft-versus-host reaction in mice.
Volk, H., Brocke, S., Osawa, H., et al. (1986) · PubMed · Cited by 14 · see citing works
Serum concentrations of soluble interleukin 2 receptor in patients with rheumatoid arthritis: effect of second line drugs.
Crilly, A., Madhok, R., Watson, J. A., et al. (1993) · Annals of the Rheumatic Diseases · doi:10.1136/ard.52.1.58 · Cited by 12 · see citing works
Soluble interleukin-2 receptor in primary and secondary Sjogren's syndrome
Tomás, S., Coll, J., & Palazon, X. (1997) · Lara D. Veeken · doi:10.1093/rheumatology/36.2.194 · Cited by 10 · see citing works
The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia
Ta, W., White, J., Goldman, C. K., et al. (1993) · Blood · doi:10.1182/blood.v82.6.1701.bloodjournal8261701 · Cited by 10 · see citing works
Serum interleukin-2 receptor for the early diagnosis of rheumatoid arthritis
Suenaga, Y., Yasuda, M., Yamamoto, M., et al. (1998) · Clinical Rheumatology · doi:10.1007/bf01451012 · Cited by 8 · see citing works
Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor
Anasetti, C., Hansen, J., Ta, W., et al. (1994) · Blood · doi:10.1182/blood.v84.4.1320.bloodjournal8441320 · Cited by 8 · see citing works
Monoclonal antibodies defining distinct epitopes of the human IL-2 receptor β chain and their differential effects on IL-2 responses
Ohbo, K., Takeshita, T., Asao, H., et al. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90293-o · Cited by 7 · see citing works
Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
Ferrant, A., Latinne, D., Bazin, H., et al. (1995) · PubMed · Cited by 6 · see citing works
Serial Measurement of Serum Interleukin-2 Receptor Levels in Patients with Rheumatoid Arthritis: Limited Evidence for a Role of T Cell Activation in Clinical Exacerbations
Ward, M. M., Pyun, E., & Pisetsky, D. S. (1994) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1994.1202 · Cited by 3 · see citing works
Zidovudine and interferon therapy for adult T-cell leukaemia/lymphoma. Results of a preliminary study at UHWI-Mona.
Wharfe, G., & Hanchard, B. (1996) · PubMed · Cited by 3 · see citing works
Interleukin receptors in lymphoid lesions. Relevance to diagnosis, biology, and therapy.
Strauchen, J. A. (1989) · PubMed · Cited by 3 · see citing works
The role of alloreactive cytotoxic and lymphokine-secreting T lymphocytes in the development of acute graft-versus-host disease
Theobald, M. (1994) · Transfusion Science · doi:10.1016/0955-3886(94)90131-7 · Cited by 2 · see citing works
Perspectives in the prevention and treatment of acute graft versus host disease.
Hervé, P. (1991) · PubMed · Cited by 2 · see citing works

Flagged first, then by citations

Research works printed but not linked: 9

Uchiyama T, Nelson DL, Fleisher TA, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells. J Immunol 1981;126: 1398-403.
Robb RJ, Munck A, Smith KA. T-cell growth factor recep- tors. J Exp Med 1982;154:1455-74.
Robb RJ, Kutny RM. Structure-function relationships for the IL-2 receptor system. J Immunol 1987;139:855-62.
IL2 receptor targeted treatment i113 www.annrheumdis.com on August 20, 2023 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/ard.59.suppl_1.i109 on 1 November 2000. Downloaded from
Wiseman LR, Faulds D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant patients. Drugs 1999;58:1029-42.
Nashan B, Niemeyer G, Koch M. Phase II clinical trial with daclizumab for prevention of acute rejection in liver trans- plant patients. [Abstract]. ASTS Proc 1998;17:266.
Waldmann TA, Greene WC, Sarin PS, Saxinger C, Blayney DW, Blattner WA, et al. Functional and phenotypic comparison of human T cell leukemia/lymphoma virus positive adult T cell leukemia with human T cell leukemia/ ymphoma virus negative Sezary leukemia, and their distinction using anti-Tac. J Clin Invest 1984;73:1711-18.
Waldmann TA, White JD, Carasquillo JA, Reynolds JC, Paik CH, Gansow OA, et al. Radioimmunotherapy of interleukin2 -expressing adult T-cell leukemia with Yttrium-90-labelled anti-Tac. Blood 1995;86:4063-75.
i114 Morris, Waldmann www.annrheumdis.com on August 20, 2023 by guest. Protected by copyright. http://ard.bmj.com/ Ann Rheum Dis: first published as 10.1136/ard.59.suppl_1.i109 on 1 November 2000. Downloaded

Sorted by citations

The Sleep-Immune Crosstalk in Health and Disease
Besedovsky, L., Lange, T., & Haack, M. (2019) · Physiological Reviews · doi:10.1152/physrev.00010.2018 · Cited by 1,479 · see citing works
Diurnal and sleep–wake dependent variations of soluble TNF- and IL-2 receptors in healthy volunteers
Haack, M., Pollmächer, T., & Mullington, J. M. (2004) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2003.12.009 · Cited by 62 · see citing works

Authors: Morris, J. C., & Waldmann, T. A.
Affiliations: National Institutes of Health (US)
ORCID: Morris, John C
Waldmann, Thomas A
Venue: Annals of the Rheumatic Diseases
Publisher: Elsevier BV
Published: 2000-11
Volume: 59
Pages: i109-i114
ISSN: 0003-4967 (ISSN-L)
DOI: 10.1136/ard.59.suppl_1.i109
OpenAlex: W2044822161
Cited by: 131
References: 87
Citations by year: 2026: 2 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 1 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 3 · 2015: 3 · 2014: 4 · 2013: 5 · 2012: 5
FWCI: 0.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Annals of the Rheumatic Diseases (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed (publishedVersion)
HighWire Press Open Archive (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
Keywords: IL-2 receptor alpha, CD25, Tac antigen, soluble interleukin-2 receptor, T cell activation, anti-Tac monoclonal antibody, allograft rejection, graft-versus-host disease, bone marrow transplantation, radioimmunoconjugates, immunotoxins, autoimmune disease, lymphoid malignancies
MeSH terms: Antibodies, Monoclonal, Autoimmune Diseases, Graft Rejection, Humans, Neoplasms, Receptors, Interleukin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Advances in interleukin 2 receptor targeted treatment

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks